FibroGen, Inc. (FGEN)

This morning I warned about an overbought group of market sectors/leaders.   Thus far, (recent leaders) retail and financials are being taken out to the woodshed.   Speculative biotech, like Intrexon  , Portola Pharmaceuticals  , SAGE Therapeutics  ...

"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly" The Good, the Bad and the Ugly" I further added to my short exposure today in a quiet, pre-Thanksgiving trading session. And now it's time to run down "The Good...

I had previously made a profitable and quick trade in FibroGen (FGEN). Several subscribers have asked me to update my view and I have continued to research the name. For a variety of reasons, I would avoid the stock now.

This is an odd market right now.

Hopes for a NASH treatment on the rise. FibroGen (FGEN) traded +23% yesterday on positive FDA data. 

I am bidding $25.25 for FibroGen (FGEN), which I recently sold.  FGEN has been hit in the biotech massacre today.

For now, FibroGen (FGEN) was a good sale.

Some updates on Friday's trades Since I was out on Friday on research assignments, I wanted to update my portfolio changes made late that day -- mostly into the teeth of the steep market decline. Most of these changes were detailed in my Columnist C...

I am not selling this. A recent speculative buy of mine, FibroGen (FGEN), is trading up another $4 today -- or 15% -- after an outsized gain late last week.  I am not selling this position.

FGEN going parabolic now. I still don't have a substantive reason for today's surge.

Anyone know why? Recent buy FibroGen (FGEN) is ahead by more than 10% this morning. I don't see an obvious reason for the rip. Does anyone see news? That said, I am sticking with this name.

It's a funny investing world. I can spend months researching a company (e.g. Ocwen (OCN)) and get schmeissed, but I spend two hours reading Fibrogen's (FGEN) IPO prospectus and I have a winner (with relatively limited knowledge away from the documen...

A quick look at my holdings. At the suggestion of several subscribers, I have agreed to put weightings on my individual holdings going forward. I forgot to do it this morning on companies mentioned today, so here's a quick update. Small: Ocwen (OCN)...

An intriguing company. Last week I bought into a small biotech company, Fibrogen (FGEN), which just came public. I did it solely on the basis of reading the prospectus -- seems like an interesting speculation. More to come.

A promising spec. I am long a small position in FibroGen (FGEN) -- a biotech whose initial public offering was priced today. I'll have more on this name in the week ahead, as I am not done with my research. Speculative but promising.